News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

•

EMERGENT BIOSOLUTIONS, Inc. Add to My Watchlist

(NYSE: EBS)

14.23

+0.04 (+0.28%)

70,040

EMERGENT BIOSOLUTIONS, Inc.
300 Professional Drive
Suite 250
Gaithersburg, MD 20879
http://www.emergentbiosolutions.com

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that induce or assist the body's immune system to prevent or treat disease. Co. operates in two business segments: biodefense and commercial. In Co.'s biodefense business, Co. develops, manufacture and commercialize immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. In Co.'s commercial business, Co. develops immunobiotics for use against infectious diseases with significant unmet or underserved medical needs.

Industry	Health
Sector	Pharmaceuticals
# of Employees	494
Shares Outstanding	30.8M
Market Cap	438.3M
Enterprise Value	-

52-Week High	$27.00
52-Week Low	$9.15
P/E Ratio	15.81
EPS	$0.90/shr
Dividend	-
Yield	-

Mr. Fuad El-Hibri

Chief Executive Officer; Chairman

Mr. R. Don Elsey

Chief Financial Officer; Treasurer; Vice President

Mr. Daniel J. Abdun-Nabi

Chief Operating Officer; President; Secretary

Dr. Steven N. Chatfield Ph.D.

Chief Scientific Officer; Subsidiary Officer

Robert G. Kramer Sr.

Executive Vice President; Subsidiary Officer

Mr. Mauro Gibellini

Senior Vice President

Mr. Kyle W. Keese

Senior Vice President

Dr. Thomas K. Zink M.D.

Senior Vice President; Chief Medical Officer

Ms. Denise Esposito

Senior Vice President; General Counsel

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Market News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs